Buffington Mohr McNeal Buys 169 Shares of Danaher Co. (NYSE:DHR)

Buffington Mohr McNeal grew its stake in Danaher Co. (NYSE:DHR) by 0.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 62,954 shares of the conglomerate’s stock after acquiring an additional 169 shares during the quarter. Danaher accounts for 2.4% of Buffington Mohr McNeal’s holdings, making the stock its 13th biggest position. Buffington Mohr McNeal’s holdings in Danaher were worth $14,451,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently bought and sold shares of the company. FMR LLC grew its position in shares of Danaher by 15.8% in the third quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock valued at $6,566,116,000 after purchasing an additional 3,217,631 shares during the last quarter. Massachusetts Financial Services Co. MA increased its position in Danaher by 17.6% during the third quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock worth $996,141,000 after acquiring an additional 535,254 shares during the period. International Assets Investment Management LLC raised its holdings in Danaher by 40,196.5% in the 3rd quarter. International Assets Investment Management LLC now owns 429,964 shares of the conglomerate’s stock valued at $119,539,000 after buying an additional 428,897 shares during the last quarter. Montrusco Bolton Investments Inc. grew its holdings in Danaher by 30.4% during the 3rd quarter. Montrusco Bolton Investments Inc. now owns 1,705,884 shares of the conglomerate’s stock worth $465,617,000 after acquiring an additional 397,671 shares during the last quarter. Finally, Union Bancaire Privee UBP SA acquired a new position in shares of Danaher during the fourth quarter worth $74,551,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Stifel Nicolaus increased their price target on Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a research note on Wednesday, October 23rd. Robert W. Baird reduced their price objective on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. Bank of America upgraded shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price target for the company in a report on Friday, December 13th. UBS Group dropped their price objective on shares of Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a report on Wednesday, October 23rd. Finally, Wolfe Research upgraded Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 target price for the company in a research note on Thursday, October 31st. Six analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $285.55.

Danaher Price Performance

NYSE DHR opened at $250.51 on Tuesday. The firm’s 50-day simple moving average is $235.33 and its two-hundred day simple moving average is $253.62. The company has a market cap of $180.94 billion, a PE ratio of 47.81, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83. Danaher Co. has a 52 week low of $225.42 and a 52 week high of $281.70. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be given a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.43%. The ex-dividend date of this dividend is Friday, December 27th. Danaher’s dividend payout ratio is presently 20.61%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.